International Assets Investment Management LLC Boosts Stock Position in Repligen Co. (NASDAQ:RGEN)

International Assets Investment Management LLC increased its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 18,449.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 58,615 shares of the biotechnology company's stock after purchasing an additional 58,299 shares during the period. International Assets Investment Management LLC owned approximately 0.10% of Repligen worth $10,539,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Signaturefd LLC boosted its position in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock valued at $45,000 after buying an additional 86 shares during the period. First Horizon Advisors Inc. raised its holdings in Repligen by 14.8% in the 3rd quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company's stock worth $107,000 after purchasing an additional 87 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in Repligen by 3.2% in the 3rd quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company's stock worth $509,000 after purchasing an additional 100 shares in the last quarter. State of Michigan Retirement System raised its holdings in Repligen by 0.8% in the 4th quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $2,239,000 after purchasing an additional 100 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Repligen by 2.5% in the 3rd quarter. Teacher Retirement System of Texas now owns 4,098 shares of the biotechnology company's stock worth $652,000 after purchasing an additional 101 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on RGEN. Stifel Nicolaus upped their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. KeyCorp increased their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research note on Thursday, February 15th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Repligen from $230.00 to $200.00 and set an "overweight" rating for the company in a research note on Thursday. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $197.75.

Insider Buying and Selling

In related news, VP Ralf Kuriyel sold 3,517 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company's stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Repligen news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now owns 87,367 shares of the company's stock, valued at $16,892,409.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is owned by insiders.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $0.99 during trading on Monday, reaching $168.04. 458,055 shares of the company traded hands, compared to its average volume of 540,167. The firm has a 50 day simple moving average of $180.81 and a 200-day simple moving average of $174.32. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $9.39 billion, a PE ratio of 668.23, a P/E/G ratio of 5.58 and a beta of 1.03. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analysts' expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business's revenue was down 17.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 EPS. Equities research analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.